Aravinda M de Silva Selected Research

Antibodies

12/2021	A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies.
2/2021	Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.
1/2021	Performance of Dried Blood Spots Compared with Serum Samples for Measuring Dengue Seroprevalence in a Cohort of Children in Cebu, Philippines.
1/2020	Serologic surveillance of maternal Zika infection in a prospective cohort in Leon, Nicaragua during the peak of the Zika epidemic.
10/2019	Oligomeric state of the ZIKV E protein defines protective immune responses.
3/2019	Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.
1/2019	Human antibody response to Zika targets type-specific quaternary structure epitopes.
1/2019	Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.
1/2019	Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
1/2019	Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aravinda M de Silva Research Topics

Disease

51	Infections 01/2022 - 06/2007
39	Dengue (Dengue Fever) 01/2022 - 03/2010
10	Severe Dengue 01/2017 - 09/2010
7	COVID-19 01/2022 - 01/2020
7	Zika Virus Infection 01/2020 - 01/2017
7	Coinfection 05/2017 - 09/2009
4	Virus Diseases (Viral Diseases) 11/2020 - 10/2014
4	Yellow Fever 01/2018 - 02/2017
3	Flavivirus Infections 01/2019 - 12/2005
3	Lyme Disease (Disease, Lyme) 06/2007 - 02/2003
2	Convalescence 01/2018 - 01/2017
1	Severe Acute Respiratory Syndrome 01/2022
1	Common Cold 05/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Breakthrough Infections 01/2021
1	Viremia 01/2018
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2018
1	Hepatitis B 01/2018
1	Japanese Encephalitis 01/2018
1	Cytokine Release Syndrome 07/2015
1	Fever (Fevers) 02/2015
1	Human Influenza (Influenza) 02/2014
1	Shock 03/2012
1	Arthritis (Polyarthritis) 06/2007
1	West Nile Fever 12/2005
1	Venezuelan Equine Encephalomyelitis 09/2003

Drug/Important Bio-Agent (IBA)

35	AntibodiesIBA 12/2021 - 12/2005
32	Neutralizing AntibodiesIBA 01/2022 - 03/2010
28	VaccinesIBA 01/2022 - 02/2003
25	EpitopesIBA 12/2021 - 09/2009
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2005
12	Monoclonal AntibodiesIBA 01/2019 - 03/2010
8	Dengue VaccinesIBA 06/2021 - 01/2012
7	AntigensIBA 01/2022 - 06/2013
6	Immune Sera (Antisera)IBA 11/2021 - 01/2012
6	Immunoglobulin G (IgG)IBA 06/2021 - 10/2016
4	Blocking AntibodiesIBA 01/2018 - 03/2012
4	CytokinesIBA 01/2018 - 03/2012
4	Fc Receptors (Fc Receptor)IBA 01/2016 - 06/2011
3	Subunit VaccinesIBA 01/2022 - 10/2016
3	Glycoproteins (Glycoprotein)IBA 12/2021 - 01/2012
3	Peptides (Polypeptides)IBA 11/2021 - 12/2017
3	Attenuated VaccinesIBA 01/2018 - 01/2017
3	Broadly Neutralizing AntibodiesIBA 05/2017 - 02/2015
2	EnzymesIBA 11/2021 - 01/2018
2	ImmunosorbentsIBA 11/2021 - 01/2018
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2021 - 06/2007
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 08/2015
2	OspA proteinIBA 09/2003 - 02/2003
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 11/2021
1	Immunoglobulins (Immunoglobulin)IBA 06/2021
1	Viral RNAIBA 11/2020
1	Virus-Like Particle VaccinesIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	difluprednate FDA Link 01/2018
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 10/2016
1	Immunoglobulin M (IgM)IBA 10/2016
1	Syk KinaseIBA 07/2015
1	InflammasomesIBA 01/2015
1	Viral AntigensIBA 10/2014
1	Immunoglobulin Fab FragmentsIBA 10/2014

Therapy/Procedure

2	Therapeutics 09/2010 - 12/2005